IL33 and chronic obstructive pulmonary disease: Tozorakimab is an anti-IL-33 monoclonal antibody currently undergoing a phase 3 clinical trial to assess its efficacy in COPD and in patients hospitalized with viral lower respiratory tract infections [192, 193].